Abstract

Using Corticosteroids to Reshape the Gut Microbiome: Implications for Inflammatory Bowel Diseases

Huang EY1, Inoue T, Leone VA, Dalal S, Touw K, Wang Y, Musch MW, Theriault B, Higuchi K, Donovan S, Gilbert J, Chang EB. Inflamm Bowel Dis. 2015 Mar 3. [Epub ahead of print]
 
     
Author information

1*Department of Medicine, Knapp Center for Biomedical Discovery, University of Chicago, Chicago, Illinois; †2nd Department of Internal Medicine, Osaka Medical College, Takatsuki, Japan; ‡Department of Surgery, University of Chicago, Chicago, Illinois; §Department of Food Science and Human Nutrition, University of Illinois, Urbana, Illinois; ‖Biosciences Division, Argonne National Laboratory, Argonne, Illinois; ¶Department of Ecology and Evolution, University of Chicago, Chicago, Illinois; **Marine Biological Laboratory, Woods Hole, Massachusetts; and ††College of Environmental and Resource Sciences, Zhejiang University, Hangzhou, China.

Abstract

BACKGROUND: Commensal gut microbiota play an important role in regulating metabolic and inflammatory conditions. Reshaping intestinal microbiota through pharmacologic means may be a viable treatment option. We sought to delineate the functional characteristics of glucocorticoid-mediated alterations on gut microbiota and their subsequent repercussions on host mucin regulation and colonic inflammation.

METHODS: Adult male C57Bl/6 mice, germ-free, Muc2-heterozygote (±), or Muc2-knockout (-/-) were injected with dexamethasone, a synthetic glucocorticoid, for 4 weeks. Fecal samples were collected for gut microbiota analysis through 16S rRNA terminal restriction fragment length polymorphism and amplicon sequencing. Intestinal mucosa was collected for mucin gene expression studies. Germ-free mice were conventionalized with gut microbes from treated and nontreated groups to determine their functional capacities in recipient hosts.

RESULTS: Exposure to dexamethasone in wild-type mice led to substantial shifts in gut microbiota over a 4-week period. Furthermore, a significant downregulation of colonic Muc2 gene expression was observed after treatment. Muc2-knockout mice harbored a proinflammatory environment of gut microbes, characterized by the increase or decrease in prevalence of specific microbiota populations such as Clostridiales and Lactobacillaceae, respectively. This colitogenic phenotype was transmissible to IL10-knockout mice, a genetically susceptible model of colonic inflammatory disorders. Microbiota from donors pretreated with dexamethasone, however, ameliorated symptoms of inflammation.

CONCLUSIONS: Commensal gut bacteria may be a key mediator of the anti-inflammatory effects observed in the large intestine after glucocorticoid exposure. These findings underscore the notion that intestinal microbes comprise a "microbial organ" essential for host physiology that can be targeted by therapeutic approaches to restore intestinal homeostasis.

© Copyright 2013-2017 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.